全文获取类型
收费全文 | 99篇 |
免费 | 5篇 |
国内免费 | 15篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 1篇 |
基础医学 | 16篇 |
口腔科学 | 1篇 |
临床医学 | 28篇 |
内科学 | 28篇 |
皮肤病学 | 4篇 |
神经病学 | 2篇 |
特种医学 | 7篇 |
外科学 | 1篇 |
预防医学 | 12篇 |
眼科学 | 1篇 |
药学 | 13篇 |
肿瘤学 | 3篇 |
出版年
2023年 | 1篇 |
2021年 | 1篇 |
2019年 | 1篇 |
2018年 | 2篇 |
2017年 | 2篇 |
2013年 | 2篇 |
2012年 | 11篇 |
2011年 | 7篇 |
2010年 | 4篇 |
2009年 | 8篇 |
2008年 | 6篇 |
2007年 | 9篇 |
2006年 | 7篇 |
2005年 | 4篇 |
2004年 | 3篇 |
2003年 | 3篇 |
2002年 | 4篇 |
2001年 | 3篇 |
2000年 | 3篇 |
1999年 | 3篇 |
1998年 | 4篇 |
1997年 | 6篇 |
1996年 | 3篇 |
1995年 | 2篇 |
1993年 | 1篇 |
1992年 | 5篇 |
1991年 | 7篇 |
1989年 | 2篇 |
1988年 | 1篇 |
1987年 | 3篇 |
1984年 | 1篇 |
排序方式: 共有119条查询结果,搜索用时 15 毫秒
1.
For the empiric management of community-acquired pneumonia, ciprofloxacin (750 mg b.i.d.) was compared with two antibiotics frequently used in this indication, i.e., amoxicillin + clavulanic acid and erythromycin. One hundred and forty-two patients were randomized in this prospective study. Among them, the 63 patients with bacteriologically documented disease were evaluated. Clinical recovery was achieved in 73.3% of patients in the ciprofloxacin group (22/30) versus 81.8% of patients in the amoxicillin + clavulanic acid or erythromycin group (27/33) (non-significant difference). Clinical failures seen with ciprofloxacin were found to be correlated with recovery of Streptococcus pneumoniae. Ciprofloxacin is effective in pneumonia but should be used only in cases where Streptococcus pneumoniae can be excluded as the causative agent. 相似文献
2.
F Ajana 《Archives de pédiatrie》2006,13(9):1269-1274
Hepatitis B is the most known viral hepatitis, and often turns into a media event in France. Its prevalence and incidence depend on countries, regions, and their inhabitants. The virus is highly infectious with a high genomic variability. Its immune reaction and pathology seem complex, but the latest consensus conferences gave a practical management. If Papillomavirus vaccine is ready and coming soon as the second STD vaccine, hepatitis B vaccine is available since 1982, and used with a real success. Fighting hepatitis B is to continue all together to immunize children and babies born from infected mothers, to adopt universal health workers precautions, to educate and modify high risk behaviours, to treat and prevent hepatitis B complications and superinfections, and finally to monitor and detect any resistant hepatitis B strain. 相似文献
3.
4.
5.
6.
7.
8.
Bocket L Cheret A Deuffic-Burban S Choisy P Gerard Y de la Tribonnière X Viget N Ajana F Goffard A Barin F Mouton Y Yazdanpanah Y 《Antiviral therapy》2005,10(2):247-254
OBJECTIVE: The effectiveness of antiretroviral treatment (ART) was compared in 416 naive patients from a French clinical cohort infected with B and non-B HIV-1 subtypes. METHODS: Time to HIV viral load (VL) undetectability was calculated for each subtype group. Three other parameters were estimated 3, 6 and 12 months after enrolment: clinical progression (that is, AIDS-defining events or death), changes in CD4 cell counts from baseline and proportion of patients achieving an undetectable VL (<400 HIV-RNA copies/ml). RESULTS: In this cohort, 317 patients (76%) were infected with a B subtype and 99 (24%) with a non-B subtype. Median time to VL undetectability was similar in the B subtype group [147 days, 95% confidence interval (CI) 119-165] and non-B subtype group (168 days, 95% CI: 105-234; P=0.16). After adjusting for AIDS-defining events at enrolment, baseline CD4 cell counts and VL, and for the treatment on which patients were initiated, no association was found between HIV subtypes and time to VL undetectability (B subtype vs non-B subtype: hazard ratio=0.80, 95% CI: 0.62-1.02, P=0.07). In the 3, 6 and 12 months after enrolment, subtype had no impact on clinical progression, CD4 cell count or VL responses to ART. This suggests that B and non-B subtypes do not affect first-line therapy efficacy, which is encouraging in view of the worldwide spread of non-B HIV-1 subtypes and the increasing availability of ART in developing countries. However, in this study we did not take into account individual non-B subtype species, therefore further studies should be designed to evaluate the efficacy of these regimens in patients with particular non-B subtypes. 相似文献
9.
Bahr GM De La Tribonniere X Darcissac E Ajana F Bocket L Sissoko D Yazdanpanah Y Dewulf J Amiel C Mouton Y 《The Journal of antimicrobial chemotherapy》2003,51(6):1377-1388
In an effort to evaluate the potential of non-specific immunotherapy in restoring global immunity, we have examined the clinical tolerance and biological effects of a 6 week administration of the immunomodulator, murabutide, in chronically infected HIV-1 patients. Forty-two subjects, presenting weak immune reconstitution and ineffective virus suppression following long-term highly active antiretroviral therapy (HAART), were randomized to receive, or not, murabutide 7 mg/day on five consecutive days/week. Clinical and immunological parameters were monitored before and after the immunotherapy period. Administration of murabutide was generally well tolerated, although some grade III adverse events, reversible on treatment cessation, were observed. Interestingly, in comparison with pre-inclusion levels, at 1 week after the immunotherapy cycle, only murabutide recipients presented a significant increase in CD4 cells, platelet counts, and in the percentage of patients with undetectable viral loads (<50 copies/mL). Statistical significance between the two groups was only evident with the latter parameter. Some of these clinical changes were maintained even up to 12 weeks after murabutide administration, and were accompanied by an increased ability to mount cellular responses to active immunization with a recall antigen, and by a significant increase in the percentage of patients presenting positive lymphoproliferative responses to the viral antigen gp160. These results warrant further evaluation of extended periods or cycles of murabutide immunotherapy as adjunct to HAART. 相似文献
10.
B. Bournique A. Akar H. Broly F. Ajana R. Counis R. Scholler 《Molecular and cellular probes》1992,6(6):443-450
To study the polymerase chain reaction (PCR) performance in detecting human immunodeficiency virus (HIV) infections, we tested 53 HIV-1 seropositive patients and 29 HIV-1 seronegative subjects for four different HIV-1 DNA regions. Fifty-one seropositive patients were found positive by PCR with at least one primer pair, but two were repeatedly negative for all primers. Weekly blood samples from 12 seropositive subjects all detected positive for at least one primer pair, but for three patients an irregular primer detection pattern was found. One additional HIV-1 seropositive sample, found negative for HIV DNA, was also negative for the beta-globin PCR control. The 29 seronegative specimens were HIV-1 DNA negative, as was a HIV-2 seropositive patient. This study demonstrates that PCR is almost as good as serological tests for detecting HIV infections, with a specificity of 100% and a sensitivity of 96% and that resampling the patients may improve detection performance. 相似文献